Neurocrine Biosciences (NBIX) Operating Margin (2010 - 2026)
Neurocrine Biosciences (NBIX) posted Operating Margin of 23.74% for Q1 2026, down 9.31% on a QoQ basis from 26.18% in Q4 2025, and up 1962.0% year-over-year from 1.15% in Q1 2025.
Neurocrine Biosciences (NBIX) Operating Margin (2010 - 2026) Analysis & Trends
Neurocrine Biosciences' Operating Margin history runs 16 years deep, the most recent figure standing at 23.74% for Q1 2026.
- Quarterly Operating Margin rose 1962.0% year-over-year to 23.74% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 25.43% (up 492.0% YoY) and the FY2025 annual result came in at 21.64%, down 258.0% from the prior year.
- Operating Margin was 23.74% for Q1 2026 at Neurocrine Biosciences, down from 26.18% in the prior quarter.
- Across five years, Operating Margin topped out at 273.5% in Q2 2022 and bottomed at 27.16% in Q1 2023.
- A 5-year average of 33.54% and a median of 23.74% in 2026 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2022 — Operating Margin jumped 25176 bps — and 2023, when it sank 25724 bps.
- Neurocrine Biosciences' Operating Margin stood at 25.1% in 2022, then increased by 16 bps to 29.17% in 2023, then dropped by 22 bps to 22.62% in 2024, then increased by 16 bps to 26.18% in 2025, then retreated by 9 bps to 23.74% in 2026.
- Business Quant data shows NBIX's Operating Margin at 23.74% in Q1 2026, 26.18% in Q4 2025, and 30.07% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 8.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.74% |
| Dec 31, 2025 | 26.18% |
| Sep 30, 2025 | 30.07% |
| Jun 30, 2025 | 21.18% |
| Mar 31, 2025 | 4.12% |
| Dec 31, 2024 | 22.62% |
| Sep 30, 2024 | 29.55% |
| Jun 30, 2024 | 24.64% |
| Mar 31, 2024 | 19.27% |
| Dec 31, 2023 | 29.17% |
| Sep 30, 2023 | 28.31% |
| Jun 30, 2023 | 16.26% |
| Mar 31, 2023 | -27.16% |
| Dec 31, 2022 | 25.10% |
| Sep 30, 2022 | 22.63% |
| Jun 30, 2022 | 273.50% |
| Mar 31, 2022 | 1.00% |
| Dec 31, 2021 | -11.63% |
| Sep 30, 2021 | 15.03% |
| Jun 30, 2021 | 21.74% |